These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27100310)

  • 1. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?
    Sun J; Ren L; Wirtz V
    J Med Econ; 2016 Sep; 19(9):881-8. PubMed ID: 27100310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.
    Heinze G; Hronsky M; Reichardt B; Baumgärtel C; Müllner M; Bucsics A; Winkelmayer WC
    Appl Health Econ Health Policy; 2015 Apr; 13(2):193-205. PubMed ID: 25536928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
    Zeng W
    BMC Health Serv Res; 2013 Oct; 13():390. PubMed ID: 24093493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic medications for you, but brand-name medications for me.
    Keenum AJ; Devoe JE; Chisolm DJ; Wallace LS
    Res Social Adm Pharm; 2012; 8(6):574-8. PubMed ID: 22357268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
    Lessing C; Ashton T; Davis P
    Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Zealand patients' understanding of brand substitution and opinions on copayment options for choice of medicine brand.
    Lessing C; Ashton T; Davis P
    Aust Health Rev; 2016 Jun; 40(3):345-350. PubMed ID: 26363980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The generics in transplantation and the rules on their use.
    Masri M
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
    Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
    JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing efficiency of proton pump inhibitors in China: influence and future directions.
    Zeng W; Finlayson AE; Shankar S; de Bruyn W; Godman B
    BMC Health Serv Res; 2015 Jan; 15():11. PubMed ID: 25609265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.